Revolution Medicines, Inc. (RVMD)
RVMD Stock Price Chart
Explore Revolution Medicines, Inc. interactive price chart. Choose custom timeframes to analyze RVMD price movements and trends.
RVMD Company Profile
Discover essential business fundamentals and corporate details for Revolution Medicines, Inc. (RVMD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Feb 2020
Employees
616.00
Website
https://www.revmed.comCEO
Mark A. Goldsmith
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
RVMD Financial Timeline
Browse a chronological timeline of Revolution Medicines, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$1.22, while revenue estimate is $1.95M.
Earnings released on 6 Aug 2025
EPS came in at -$1.31 falling short of the estimated -$0.94 by -39.36%.
Earnings released on 7 May 2025
EPS came in at -$1.13 falling short of the estimated -$1.12 by -0.89%.
Earnings released on 26 Feb 2025
EPS came in at -$1.12 falling short of the estimated -$1.01 by -10.89%, while revenue for the quarter reached $261.59M , beating expectations by +75.47K%.
Earnings released on 6 Nov 2024
EPS came in at -$0.94 falling short of the estimated -$0.89 by -5.24%.
Earnings released on 7 Aug 2024
EPS came in at -$0.81 falling short of the estimated -$0.77 by -5.19%.
Earnings released on 8 May 2024
EPS came in at -$0.70 surpassing the estimated -$0.75 by +6.21%.
Earnings released on 26 Feb 2024
EPS came in at -$1.14 falling short of the estimated -$0.86 by -32.56%, while revenue for the quarter reached $742.00K , missing expectations by -31.93%.
Earnings released on 6 Nov 2023
EPS came in at -$0.99 surpassing the estimated -$1.01 by +1.98%.
Earnings released on 8 Aug 2023
EPS came in at -$0.92 falling short of the estimated -$0.83 by -10.84%, while revenue for the quarter reached $3.82M , beating expectations by +145.13%.
Earnings released on 8 May 2023
EPS came in at -$0.72 surpassing the estimated -$0.84 by +14.29%, while revenue for the quarter reached $7.01M , beating expectations by +138.57%.
Earnings released on 27 Feb 2023
EPS came in at -$0.63 surpassing the estimated -$0.84 by +25.00%, while revenue for the quarter reached $15.33M , beating expectations by +96.47%.
Earnings released on 7 Nov 2022
EPS came in at -$0.87 matching the estimated -$0.87, while revenue for the quarter reached $3.36M , missing expectations by -47.04%.
Earnings released on 9 Aug 2022
EPS came in at -$0.82 surpassing the estimated -$0.87 by +5.75%, while revenue for the quarter reached $9.12M , beating expectations by +29.89%.
Earnings released on 9 May 2022
EPS came in at -$0.78 surpassing the estimated -$0.82 by +4.88%, while revenue for the quarter reached $7.58M , missing expectations by -11.71%.
Earnings released on 28 Feb 2022
EPS came in at -$0.71 falling short of the estimated -$0.65 by -9.23%, while revenue for the quarter reached $9.46M , beating expectations by +5.23%.
Earnings released on 10 Nov 2021
EPS came in at -$0.72 falling short of the estimated -$0.62 by -16.13%, while revenue for the quarter reached $1.10M , beating expectations by +19.23%.
Earnings released on 11 Aug 2021
EPS came in at -$0.60 falling short of the estimated -$0.55 by -9.09%, while revenue for the quarter reached $8.70M , meeting expectations.
Earnings released on 10 May 2021
EPS came in at -$0.53 falling short of the estimated -$0.52 by -1.92%, while revenue for the quarter reached $10.13M , beating expectations by +1.96%.
Earnings released on 2 Mar 2021
EPS came in at -$0.52 falling short of the estimated -$0.37 by -40.54%, while revenue for the quarter reached $8.75M .
Earnings released on 12 Nov 2020
EPS came in at -$0.42 falling short of the estimated -$0.39 by -7.69%, while revenue for the quarter reached $12.66M , beating expectations by +8.33%.
RVMD Stock Performance
Access detailed RVMD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.